title: Outpatient parenteral antibiotic therapy for bone and joint infections: an italian multicenter study.
abstract: In the early eighties, the advantages of outpatient parenteral antibiotic therapy (OPAT) (reduced costs, no hospitalization trauma in children, no immobilization syndrome in elderly, reduction in nosocomial infections by multiresistant organisms) were identified in the United States, and suitable therapeutic programs were established. Currently, more than 250,000 patients per year are treated according to an OPAT program. In order to understand the different ways of managing OPAT and its results, a National OPAT Registry was set up in 2003 in Italy. Analysis of data concerning osteomyelitis, septic arthritis, prosthetic joint infection and spondylodiskitis, allowed information to be acquired about 239 cases of bone and joint infections, with particular concern to demographics, therapeutic management, clinical response, and possible side effects. Combination therapy was the first-line choice in 66.9% of cases and frequently intravenous antibiotics were combined with oral ones. Teicoplanin (38%) and ceftriaxone (14.7%), whose pharmacokinetic/pharmacodynamic properties permit once-a-day administration, were the two top antibiotics chosen; fluoroquinolones (ciprofloxacin and levofloxacin) were the most frequently utilized oral drugs. Clinical success, as well as patients' and doctors' satisfaction with the OPAT regimen was high. Side-effects were mild and occurred in 11% of cases. These data confirm that the management of bone and joint infections in an outpatient setting is suitable, effective and safe.
authors.affiliation: Dipartimento di Malattie Infettive, Seconda Universita degli Studi, Napoli, Italy. silvanoesposito@libero.it
authors.forename: S
authors.initials: S
authors.lastname: Esposito
authors.forename: S
authors.initials: S
authors.lastname: Leone
authors.forename: S
authors.initials: S
authors.lastname: Noviello
authors.forename: F
authors.initials: F
authors.lastname: Ianniello
authors.forename: M
authors.initials: M
authors.lastname: Fiore
authors.forename: M
authors.initials: M
authors.lastname: Russo
authors.forename: G
authors.initials: G
authors.lastname: Foti
authors.forename: M S
authors.initials: MS
authors.lastname: Carpentieri
authors.forename: C
authors.initials: C
authors.lastname: Cellesi
authors.forename: G
authors.initials: G
authors.lastname: Zanelli
authors.forename: A
authors.initials: A
authors.lastname: Cellini
authors.forename: C
authors.initials: C
authors.lastname: Girmenia
authors.forename: F
authors.initials: F
authors.lastname: De Lalla
authors.forename: A
authors.initials: A
authors.lastname: Maiello
authors.forename: P
authors.initials: P
authors.lastname: Maio
authors.forename: F
authors.initials: F
authors.lastname: Marranconi
authors.forename: S
authors.initials: S
authors.lastname: Sabbatani
authors.forename: M
authors.initials: M
authors.lastname: Pantaleoni
authors.forename: F
authors.initials: F
authors.lastname: Ghinelli
authors.forename: M L
authors.initials: ML
authors.lastname: Soranzo
authors.forename: P
authors.initials: P
authors.lastname: Vigano
authors.forename: T
authors.initials: T
authors.lastname: Re
authors.forename: P
authors.initials: P
authors.lastname: Viale
authors.forename: L
authors.initials: L
authors.lastname: Scudeller
authors.forename: F
authors.initials: F
authors.lastname: Scaglione
authors.forename: V
authors.initials: V
authors.lastname: Vullo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care / Q000379:methods*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001170:Arthritis, Infectious / Q000188:drug therapy / Q000628:therapy*; D001850:Bone Diseases, Infectious / Q000188:drug therapy / Q000628:therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007267:Injections; D007558:Italy; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents